<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563093</url>
  </required_header>
  <id_info>
    <org_study_id>GRC57</org_study_id>
    <secondary_id>U1111-1161-2491</secondary_id>
    <nct_id>NCT02563093</nct_id>
  </id_info>
  <brief_title>Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults</brief_title>
  <official_title>Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2015-2016 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety and immunogenicity of the 2015-2016
      formulations of Fluzone Quadrivalent and Fluzone Intradermal Quadrivalent vaccines in adults
      18 to &lt; 65 years of age, and of the 2015-2016 formulations of Fluzone Quadrivalent and
      Fluzone High-Dose vaccines in adults ≥ 65 years of age.

      Primary Objective:

      - To describe the safety of the 2015-2016 formulations of Fluzone Quadrivalent and Fluzone
      Intradermal Quadrivalent vaccines in adults 18 to &lt; 65 years of age and the safety of the
      2015-2016 formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65
      years of age.

      Observational Objectives:

        -  To describe the immunogenicity of the 2015-2016 formulations of Fluzone Quadrivalent and
           Fluzone Intradermal Quadrivalent vaccines in adults 18 to &lt; 65 years of age and the
           immunogenicity of the 2015-2016 formulations of Fluzone Quadrivalent and Fluzone
           High-Dose vaccines in adults ≥ 65 years of age.

        -  To evaluate the compliance, in terms of immunogenicity, of each study vaccine (Fluzone
           Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose) in the applicable
           age group with the historical requirements of the Committee for Human Medicinal Products
           (CHMP) Note for Guidance (NfG) Committee for Propriety Medicinal Products (CPMP) - CHMP
           NfG CPMP/BWP/214/96.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults age 18 to &lt; 65 years will be randomly assigned to receive either Fluzone Quadrivalent
      or Fluzone Intradermal Quadrivalent vaccine and adults age ≥ 65 years will be randomly
      assigned to receive either Fluzone Quadrivalent or Fluzone High-Dose vaccine. All subjects
      will receive a single dose of their randomly assigned vaccine.

      They will be followed from Visit 1 to Visit 2 for evaluation of safety outcomes. Solicited
      adverse reactions will be collected for 7 days after vaccination. Unsolicited non-serious
      adverse events (AEs) and serious adverse events (SAEs) will be collected from Visit 1 to
      Visit 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection-Site or Systemic Reactions After Receipt of the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 solicited injection-site reactions: Pain, Significant; prevents daily activity. Erythema, Swelling, Induration, and Ecchymosis &gt;100 mm. Grade 3 solicited systemic reactions: Fever, ≥ 39.0°C or ≥ 102.1°F; Headache, Malaise, Myalgia, and Shivering, Significant; prevents daily activity.
A participant (18 to &lt; 65 Years) who was randomly assigned to receive Fluzone Intradermal Quadrivalent vaccine received Fluzone Quadrivalent vaccine instead; this participant was excluded from the Per-protocol analysis Set and was included in the Fluzone Quadrivalent vaccine Group in the Safety Analysis Set and the assigned group in the Full Analysis Set.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Influenza Antibodies Pre- and Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and 21 days post-vaccination</time_frame>
    <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Seroprotection Pre and Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</measure>
    <time_frame>Day 0 (Pre-vaccination) and 21 days post-vaccination</time_frame>
    <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay. Seroprotection was defined as the number of participants with a titer ≥ 40 (1/dilution) at pre-vaccination and 21 days post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Seroconversion Following Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</measure>
    <time_frame>21 days post-vaccination</time_frame>
    <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay. Seroconversion was defined as either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in titer post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer Ratios of Influenza Antibodies Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</measure>
    <time_frame>21 days post-vaccination</time_frame>
    <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults 18 to &lt; 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults 18 to &lt; 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative</intervention_name>
    <description>0.5 mL, Intramuscular (IM)</description>
    <arm_group_label>Study Group 1</arm_group_label>
    <other_name>Fluzone® Quadrivalent, Influenza Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Study Group 2</arm_group_label>
    <other_name>Fluzone® Intradermal Quadrivalent, Influenza Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 3</arm_group_label>
    <other_name>Fluzone® Quadrivalent, Influenza Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone High-Dose vaccine, 2015-2016 formulation</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 4</arm_group_label>
    <other_name>Fluzone® High-Dose, Influenza Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age on the day of inclusion

          -  Informed consent form has been signed and dated

          -  Able to attend all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  History of serious adverse reaction to any influenza vaccine

          -  Receipt of any vaccine within 30 days before receiving study vaccine, or plans to
             receive another vaccine before Visit 2

          -  Participation in another interventional clinical trial investigating a vaccine, drug,
             medical device, or medical procedure in the 30 days preceding the first study
             vaccination or during the course of the study, unless no intervention for the other
             study occurred within the 30 days prior to the first study vaccination and none are
             planned before the subject would complete safety surveillance for the present study

          -  Thrombocytopenia, which may be a contraindication for intramuscular vaccination, at
             the discretion of the Investigator

          -  Prior vaccination with any 2015-2016 formulation of influenza vaccine

          -  Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine
             components, or a history of a life-threatening reaction to Fluzone Quadrivalent,
             Fluzone Intradermal Quadrivalent, or Fluzone High-Dose vaccine or to a vaccine
             containing any of the same substances (the complete list of vaccine components is
             included in the Prescribing Information)

          -  Receipt of immune globulins, blood, or blood-derived products in the past 3 months

          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion,
             which may be a contraindication for intramuscular vaccination, at the discretion of
             the Investigator

          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
             non-childbearing potential, a female must be post-menopausal for at least 1 year,
             surgically sterile, or using an effective method of contraception or abstinence from
             at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             subject if enrolled or could interfere with the evaluation of the vaccine

          -  Personal history of Guillain-Barré syndrome

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C, as
             reported by the subject.

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol or drug addiction that, in the opinion of the Investigator, might
             interfere with the ability to comply with trial procedures

          -  Moderate or severe acute illness/infection (according to Investigator judgment) or
             febrile illness (temperature ≥ 100.4°F) on the day of vaccination. A prospective
             subject should not be included in the study until the condition has resolved or the
             febrile event has subsided

          -  Identified as an Investigator or employee of an Investigator or study center with
             direct involvement in the proposed study, or identified as an immediate family member
             (i.e., parent, spouse, natural or adopted child) of an Investigator or employee with
             direct involvement in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <results_first_submitted>August 26, 2016</results_first_submitted>
  <results_first_submitted_qc>October 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Fluzone® Quadrivalent, Influenza Vaccine</keyword>
  <keyword>Fluzone® Intradermal Quadrivalent, Influenza Vaccine</keyword>
  <keyword>Fluzone® High Dose, Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 28 September 2015 to 03 November 2015 at 4 clinic centers in the United States.</recruitment_details>
      <pre_assignment_details>A total of 208 participants who met all of the inclusion criteria and no exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
          <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
        </group>
        <group group_id="P2">
          <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
          <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
        </group>
        <group group_id="P3">
          <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
          <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
        </group>
        <group group_id="P4">
          <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
          <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
          <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
        </group>
        <group group_id="B2">
          <title>Fluzone Quadrivalent Intradermal Vaccine</title>
          <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
        </group>
        <group group_id="B3">
          <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
          <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
        </group>
        <group group_id="B4">
          <title>Fluzone High-Dose Vaccine</title>
          <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="13.5"/>
                    <measurement group_id="B2" value="43.4" spread="14.7"/>
                    <measurement group_id="B3" value="72.8" spread="5.2"/>
                    <measurement group_id="B4" value="74.2" spread="6.2"/>
                    <measurement group_id="B5" value="59.2" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection-Site or Systemic Reactions After Receipt of the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
        <description>Solicited injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 solicited injection-site reactions: Pain, Significant; prevents daily activity. Erythema, Swelling, Induration, and Ecchymosis &gt;100 mm. Grade 3 solicited systemic reactions: Fever, ≥ 39.0°C or ≥ 102.1°F; Headache, Malaise, Myalgia, and Shivering, Significant; prevents daily activity.
A participant (18 to &lt; 65 Years) who was randomly assigned to receive Fluzone Intradermal Quadrivalent vaccine received Fluzone Quadrivalent vaccine instead; this participant was excluded from the Per-protocol analysis Set and was included in the Fluzone Quadrivalent vaccine Group in the Safety Analysis Set and the assigned group in the Full Analysis Set.</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>The vaccine safety outcomes were assessed in the Safety Analysis Set. A participant (18 to &lt; 65 Years) who was assigned to receive Fluzone Intradermal Quadrivalent vaccine received Fluzone Quadrivalent vaccine instead; this participant was included in the Fluzone Quadrivalent vaccine (18 to &lt; 65 Years) group in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O4">
            <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection-Site or Systemic Reactions After Receipt of the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
          <description>Solicited injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 solicited injection-site reactions: Pain, Significant; prevents daily activity. Erythema, Swelling, Induration, and Ecchymosis &gt;100 mm. Grade 3 solicited systemic reactions: Fever, ≥ 39.0°C or ≥ 102.1°F; Headache, Malaise, Myalgia, and Shivering, Significant; prevents daily activity.
A participant (18 to &lt; 65 Years) who was randomly assigned to receive Fluzone Intradermal Quadrivalent vaccine received Fluzone Quadrivalent vaccine instead; this participant was excluded from the Per-protocol analysis Set and was included in the Fluzone Quadrivalent vaccine Group in the Safety Analysis Set and the assigned group in the Full Analysis Set.</description>
          <population>The vaccine safety outcomes were assessed in the Safety Analysis Set. A participant (18 to &lt; 65 Years) who was assigned to receive Fluzone Intradermal Quadrivalent vaccine received Fluzone Quadrivalent vaccine instead; this participant was included in the Fluzone Quadrivalent vaccine (18 to &lt; 65 Years) group in the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site Pain (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Induration (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Induration (N=53,51,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Ecchymosis (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Ecchymosis (N=53,51,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=52, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N=52, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (N=53, 51, 53, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Influenza Antibodies Pre- and Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
        <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay.</description>
        <time_frame>Day 0 (pre-vaccination) and 21 days post-vaccination</time_frame>
        <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an Intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O4">
            <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Influenza Antibodies Pre- and Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
          <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay.</description>
          <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
          <units>Titers (1/dilutions)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1; Pre-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274" lower_limit="173" upper_limit="433"/>
                    <measurement group_id="O2" value="196" lower_limit="134" upper_limit="286"/>
                    <measurement group_id="O3" value="160" lower_limit="109" upper_limit="234"/>
                    <measurement group_id="O4" value="62.2" lower_limit="44.4" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1; Post-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="764" lower_limit="564" upper_limit="1034"/>
                    <measurement group_id="O2" value="631" lower_limit="435" upper_limit="915"/>
                    <measurement group_id="O3" value="283" lower_limit="196" upper_limit="407"/>
                    <measurement group_id="O4" value="324" lower_limit="242" upper_limit="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Pre-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="32.0" upper_limit="76.2"/>
                    <measurement group_id="O2" value="61.9" lower_limit="44.4" upper_limit="86.3"/>
                    <measurement group_id="O3" value="48.0" lower_limit="34.4" upper_limit="67.0"/>
                    <measurement group_id="O4" value="50.1" lower_limit="36.4" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Post-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1051" lower_limit="687" upper_limit="1609"/>
                    <measurement group_id="O2" value="1033" lower_limit="717" upper_limit="1488"/>
                    <measurement group_id="O3" value="379" lower_limit="248" upper_limit="580"/>
                    <measurement group_id="O4" value="769" lower_limit="517" upper_limit="1143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata; Pre-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="118" upper_limit="293"/>
                    <measurement group_id="O2" value="307" lower_limit="208" upper_limit="454"/>
                    <measurement group_id="O3" value="208" lower_limit="147" upper_limit="293"/>
                    <measurement group_id="O4" value="134" lower_limit="101" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata; Post-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881" lower_limit="581" upper_limit="1336"/>
                    <measurement group_id="O2" value="1099" lower_limit="822" upper_limit="1469"/>
                    <measurement group_id="O3" value="438" lower_limit="311" upper_limit="617"/>
                    <measurement group_id="O4" value="471" lower_limit="352" upper_limit="632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria; Pre-vaccination (N=51,50,53,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" lower_limit="161" upper_limit="340"/>
                    <measurement group_id="O2" value="290" lower_limit="213" upper_limit="397"/>
                    <measurement group_id="O3" value="178" lower_limit="122" upper_limit="258"/>
                    <measurement group_id="O4" value="NA">B Victoria Influenza antigen not in administered vaccine for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria; Post-vaccination (N=51,50,53,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1237" lower_limit="901" upper_limit="1700"/>
                    <measurement group_id="O2" value="844" lower_limit="621" upper_limit="1149"/>
                    <measurement group_id="O3" value="355" lower_limit="260" upper_limit="485"/>
                    <measurement group_id="O4" value="NA">B Victoria Influenza antigen not in administered vaccine for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Seroprotection Pre and Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
        <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay. Seroprotection was defined as the number of participants with a titer ≥ 40 (1/dilution) at pre-vaccination and 21 days post-vaccination.</description>
        <time_frame>Day 0 (Pre-vaccination) and 21 days post-vaccination</time_frame>
        <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O4">
            <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Seroprotection Pre and Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
          <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay. Seroprotection was defined as the number of participants with a titer ≥ 40 (1/dilution) at pre-vaccination and 21 days post-vaccination.</description>
          <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1; Pre-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1; Post-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Pre-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2; Post vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata; Pre-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata; Post-vaccination (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria; Pre-vaccination (N=51,50,53,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="NA">B Victoria Influenza antigen not in administered vaccine for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria; Post-vaccination (N=51,50,53,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="NA">B Victoria Influenza antigen not in administered vaccine for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Seroconversion Following Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
        <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay. Seroconversion was defined as either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in titer post-vaccination.</description>
        <time_frame>21 days post-vaccination</time_frame>
        <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O4">
            <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Seroconversion Following Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
          <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay. Seroconversion was defined as either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in titer post-vaccination.</description>
          <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria (N=51,50,53,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="NA">B Victoria Influenza antigen not in administered vaccine for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer Ratios of Influenza Antibodies Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
        <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay.</description>
        <time_frame>21 days post-vaccination</time_frame>
        <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
            <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
          </group>
          <group group_id="O4">
            <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
            <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios of Influenza Antibodies Post-Vaccination With the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, or Fluzone High-Dose Vaccine</title>
          <description>Anti-influenza antibodies were measured using an hemagglutination inhibition assay.</description>
          <population>Anti-influenza antibodies were assessed in the Per-protocol Analysis Set.</population>
          <units>Titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" lower_limit="1.92" upper_limit="3.84"/>
                    <measurement group_id="O2" value="3.18" lower_limit="2.25" upper_limit="4.49"/>
                    <measurement group_id="O3" value="1.77" lower_limit="1.38" upper_limit="2.26"/>
                    <measurement group_id="O4" value="5.07" lower_limit="3.50" upper_limit="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="12.5" upper_limit="29.9"/>
                    <measurement group_id="O2" value="16.4" lower_limit="10.4" upper_limit="26.1"/>
                    <measurement group_id="O3" value="7.49" lower_limit="4.97" upper_limit="11.3"/>
                    <measurement group_id="O4" value="15.2" lower_limit="10.2" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata (N=51,50,53,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="3.22" upper_limit="6.98"/>
                    <measurement group_id="O2" value="3.58" lower_limit="2.52" upper_limit="5.09"/>
                    <measurement group_id="O3" value="2.11" lower_limit="1.60" upper_limit="2.78"/>
                    <measurement group_id="O4" value="3.52" lower_limit="2.59" upper_limit="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria (N=51,50,53,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" lower_limit="3.54" upper_limit="7.89"/>
                    <measurement group_id="O2" value="2.87" lower_limit="2.15" upper_limit="3.83"/>
                    <measurement group_id="O3" value="1.97" lower_limit="1.52" upper_limit="2.57"/>
                    <measurement group_id="O4" value="NA">B Victoria Influenza antigen not in administered vaccine for this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 up to Day 21 post-vaccination.</time_frame>
      <desc>A participant (18 to &lt; 65 Years) who was randomly assigned to receive Fluzone Intradermal Quadrivalent vaccine received Fluzone Quadrivalent vaccine instead; this participant was included in the Fluzone Quadrivalent vaccine (18 to &lt; 65 Years) Group in the Safety Analysis Set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluzone Quadrivalent Vaccine (18 to &lt; 65 Years)</title>
          <description>Adults 18 to &lt; 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
        </group>
        <group group_id="E2">
          <title>Fluzone Quadrivalent Intradermal Vaccine (18 to &lt; 65 Years)</title>
          <description>Adults 18 to &lt; 65 years of age who received an intradermal injection of a dose of Fluzone Intradermal Quadrivalent vaccine</description>
        </group>
        <group group_id="E3">
          <title>Fluzone Quadrivalent Vaccine (≥ 65 Years)</title>
          <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone Quadrivalent vaccine</description>
        </group>
        <group group_id="E4">
          <title>Fluzone High-Dose Vaccine (≥ 65 Years)</title>
          <description>Adults ≥ 65 years of age who received an intramuscular injection of a dose of Fluzone High-Dose vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="53"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection site Induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

